Form 4: Petros Pharmaceuticals Director Bruce Bernstein Receives 300,000 Shares of Restricted Stock

Director Bruce Bernstein acquired 300,000 shares of Petros Pharmaceuticals restricted stock on February 19, 2025, under the company's incentive plan.

Summary

• Bruce Bernstein, a director of Petros Pharmaceuticals, acquired 300,000 shares of common stock on February 19, 2025.
• The shares were granted as restricted stock under the company's Amended and Restated 2020 Omnibus Incentive Compensation Plan.
• The grant price was $0.
• 50% of the shares vest on the first anniversary of the grant date, and the remaining 50% vest on the second anniversary, contingent upon continued service to the Issuer.
• Following the transaction, Bernstein directly owns 308,346 shares of Petros Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of restricted stock is a standard practice and indicates confidence in the company's future, but it's not a major event.

Positives

• The grant of restricted stock aligns the director's interests with the long-term performance of the company.
• The vesting schedule incentivizes continued service and commitment from the director.

Future Outlook

The vesting of the restricted stock is contingent upon the director's continued service to the company over the next two years.

Industry Context

Grants of restricted stock are a common practice to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is especially common in smaller cap companies.

Stakeholder Impact

• The grant of restricted stock could have a slightly dilutive effect on existing shareholders.
• The vesting schedule incentivizes the director to contribute to the company's success, which benefits all stakeholders.

Key Dates

Keywords

Petros Pharmaceuticals, Director, Bruce Bernstein, Restricted Stock, Incentive Plan, Share Grant, Beneficial Ownership